相似文献

1

Induction of circulating phospholipase A(2) by intravenous administration of recombinant human tumour necrosis factor.

Mediators Inflamm. 1992;1(4):235-40. doi: 10.1155/S0962935192000358.

2

Tumour necrosis factor-alpha plasma levels after flavone acetic acid administration in man and mouse.

Eur J Cancer. 1993;29A(5):729-33. doi: 10.1016/s0959-8049(05)80355-7.

3

Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.

Cancer Res. 1988 Oct 15;48(20):5864-7.

4

Induction of circulating phospholipase A2 activity by intravenous infusion of endotoxin in patients with neoplasia.

J Immunother (1991). 1992 Nov;12(4):242-6. doi: 10.1097/00002371-199211000-00004.

5

Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism.

J Clin Oncol. 1988 Feb;6(2):344-50. doi: 10.1200/JCO.1988.6.2.344.

6

Nutritional parameters observed during 28-day infusion of recombinant human tumor necrosis factor-alpha.

JPEN J Parenter Enteral Nutr. 1993 Nov-Dec;17(6):541-5. doi: 10.1177/0148607193017006541.

7

Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study.

J Natl Cancer Inst. 1988 Sep 7;80(13):1039-44. doi: 10.1093/jnci/80.13.1039.

8

Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer.

Ann Oncol. 2005 Oct;16(10):1695-701. doi: 10.1093/annonc/mdi318. Epub 2005 Jul 12.

9

Recombinant human gamma interferon administered by continuous intravenous infusion in acute myelogenous leukemia and myelodysplastic syndromes.

Am J Clin Oncol. 1993 Apr;16(2):159-63. doi: 10.1097/00000421-199304000-00017.

10

Tumor necrosis factor administration is associated with increased endogenous production of M-CSF and G-CSF but not GM-CSF in human cancer patients.

Exp Hematol. 1996 Jan;24(1):49-53.

本文引用的文献

1

Extracellular phospholipase A2 mediates inflammatory hyperaemia.

Nature. 1981;293(5833):583-5. doi: 10.1038/293583a0.

2

Structure and function of phospholipase A2.

Rev Physiol Biochem Pharmacol. 1981;91:91-203. doi: 10.1007/3-540-10961-7_3.

3

Involvement of circulating phospholipase A2 in the pathogenesis of the hemodynamic changes in endotoxin shock.

Can J Physiol Pharmacol. 1983 Jun;61(6):561-6. doi: 10.1139/y83-086.

4

Prostaglandins and inflammation.

Semin Arthritis Rheum. 1980 Feb;9(3):153-90. doi: 10.1016/0049-0172(80)90006-2.

5

The endogenous mediator of endotoxic shock.

Clin Res. 1987 Apr;35(3):192-7.

6

Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study.

J Natl Cancer Inst. 1988 Sep 7;80(13):1039-44. doi: 10.1093/jnci/80.13.1039.

7

Pathogenesis of hypotension in septic shock: correlation of circulating phospholipase A2 levels with circulatory collapse.

Crit Care Med. 1988 Jan;16(1):1-7. doi: 10.1097/00003246-198801000-00001.

8

Cachectin: a hormone that triggers acute shock and chronic cachexia.

J Infect Dis. 1988 Mar;157(3):413-20. doi: 10.1093/infdis/157.3.413.

9

Edema-inducing activity of phospholipase A2 purified from human synovial fluid and inhibition by aristolochic acid.

Inflammation. 1988 Dec;12(6):549-61. doi: 10.1007/BF00914317.

10

Involvement of phospholipase A2 activation in tumour cell killing by tumour necrosis factor.

Immunology. 1988 May;64(1):81-5.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

静脉注射重组人肿瘤坏死因子诱导循环磷脂酶 A(2)。

Induction of circulating phospholipase A(2) by intravenous administration of recombinant human tumour necrosis factor.

机构信息

Inflammation Research Group University of Toronto The Wellesley Hospital 160 Wellesley St. East, Ontario Toronto M4Y 1J3 Canada.

出版信息

Mediators Inflamm. 1992;1(4):235-40. doi: 10.1155/S0962935192000358.

DOI:10.1155/S0962935192000358

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2365345/

Abstract

We have examined the effects of intravenous infusion of recombinant human tumour necrosis factor (rh-TNF) on serum activity of phospholipase A(2) (PLA(2)) in patients with malignancies. Nine patients received a 24 h continuous intravenous infusion ranging from 1.0 x 10(5) U/m(2) to 3.0 x 10(5) U/m(2); 14 patients received a 5 day continuous intravenous infusion ranging from 0.5 x 10(5) U/m(2)/day to 3.0 10(5) U/m(2)/day. Twenty one of 23 patients responded with marked increases in serum PLA(2) activity that were detectable 3 h after the beginning of the rh-TNF infusion and reached maximum levels at 18 h with a mean increase of 16.2-fold. In patients receiving a 5 day rh-TNF infusion, the highest levels of PLA(2) were observed after the first day of infusion. Serum PLA(2) activity declined continuously to 2.9-fold above baseline at the end of the infusion. A significant correlation was noted between the dose of infused rh-TNF and the maximum increase in PLA(2) activity. To our knowledge, this is the first time that an association between intravenous TNF administration and induction of circulating PLA(2) in man has been established.

摘要

我们研究了静脉内输注重组人肿瘤坏死因子（rh-TNF）对恶性肿瘤患者血清中磷酸脂酶 A2（PLA2）活性的影响。9 例患者接受 1.0×105至 3.0×105U/m2 的 24 小时连续静脉内输注；14 例患者接受 0.5×105至 3.0×105U/m2/天的 5 天连续静脉内输注。23 例患者中的 21 例对 rh-TNF 输注有明显的血清 PLA2 活性增加的反应，在 rh-TNF 输注开始后 3 小时即可检测到，并在 18 小时达到最大水平，平均增加 16.2 倍。在接受 5 天 rh-TNF 输注的患者中，在输注的第一天观察到 PLA2 的最高水平。在输注结束时，血清 PLA2 活性连续下降至基线以上 2.9 倍。注入的 rh-TNF 的剂量与 PLA2 活性的最大增加之间存在显著相关性。据我们所知，这是首次在人体内建立了静脉内 TNF 给药与诱导循环 PLA2 之间的关联。